TY - JOUR
T1 - Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric Aβ
AU - Matafora, Vittoria
AU - Gorb, Alena
AU - Yang, Fangjia
AU - Noble, Wendy
AU - Bachi, Angela
AU - Perez-Nievas, Beatriz Gomez
AU - Jimenez-Sanchez, Maria
N1 - Funding Information:
We would like to thank Cogentech Proteomics/MS Facility (IFOM) for critical comments and suggestions and Elena Galea (Universidad Autonoma de Barcelona) for her critical reading of the manuscript. This work is funded by an ARUK KCL Network Pump Priming grant (BGP‐N, MJ‐S), the Van Geest Foundation (BGP‐N), and Medical Research Council Career Development Award (MR/N022696/1) and Transition Support Award (MR/V036947/1) (MJ‐S).
Publisher Copyright:
© 2023 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Astrocytes associate with amyloid plaques in Alzheimer's disease (AD). Astrocytes react to changes in the brain environment, including increasing concentrations of amyloid-β (Aβ). However, the precise response of astrocytes to soluble small Aβ oligomers at concentrations similar to those present in the human brain has not been addressed. In this study, we exposed astrocytes to media from neurons that express the human amyloid precursor protein (APP) transgene with the double Swedish mutation (APPSwe), and which contains APP-derived fragments, including soluble human Aβ oligomers. We then used proteomics to investigate changes in the astrocyte secretome. Our data show dysregulated secretion of astrocytic proteins involved in the extracellular matrix and cytoskeletal organization and increase secretion of proteins involved in oxidative stress responses and those with chaperone activity. Several of these proteins have been identified in previous transcriptomic and proteomic studies using brain tissue from human AD and cerebrospinal fluid (CSF). Our work highlights the relevance of studying astrocyte secretion to understand the brain response to AD pathology and the potential use of these proteins as biomarkers for the disease.
AB - Astrocytes associate with amyloid plaques in Alzheimer's disease (AD). Astrocytes react to changes in the brain environment, including increasing concentrations of amyloid-β (Aβ). However, the precise response of astrocytes to soluble small Aβ oligomers at concentrations similar to those present in the human brain has not been addressed. In this study, we exposed astrocytes to media from neurons that express the human amyloid precursor protein (APP) transgene with the double Swedish mutation (APPSwe), and which contains APP-derived fragments, including soluble human Aβ oligomers. We then used proteomics to investigate changes in the astrocyte secretome. Our data show dysregulated secretion of astrocytic proteins involved in the extracellular matrix and cytoskeletal organization and increase secretion of proteins involved in oxidative stress responses and those with chaperone activity. Several of these proteins have been identified in previous transcriptomic and proteomic studies using brain tissue from human AD and cerebrospinal fluid (CSF). Our work highlights the relevance of studying astrocyte secretion to understand the brain response to AD pathology and the potential use of these proteins as biomarkers for the disease.
KW - Humans
KW - Astrocytes/metabolism
KW - Proteomics
KW - Secretome
KW - Amyloid beta-Peptides/metabolism
KW - Alzheimer Disease/metabolism
KW - Amyloid beta-Protein Precursor/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85161653955&partnerID=8YFLogxK
U2 - 10.1111/jnc.15875
DO - 10.1111/jnc.15875
M3 - Article
C2 - 37303123
SN - 0022-3042
VL - 166
SP - 346
EP - 366
JO - Journal of Neurochemistry
JF - Journal of Neurochemistry
IS - 2
ER -